Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: ASLAN004, ASLAN004 Placebo; Drug
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Fremont, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Atopic Dermatitis
Interventions: EVO756, Placebo control; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Fremont, California • Los Angeles, California + 21 more

Conditions: Breast Cancer
Interventions: SureTouch; Device
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more

Conditions: Acne Vulgaris
Interventions: Tazarotene (Patch application in Challenge Phase); Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Healthy, Atopic Dermatitis
Interventions: Trier Social Stress Test (TSST), Landscape Video; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hereditary Angioedema
Interventions: Donidalorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 2 Years to 13 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Palo Alto, California • Aurora, Colorado

Conditions: Urticaria Chronic
Interventions: Placebo, 0.5 mg epinephrine, 1 mg epinephrine; Drug
Lead sponsor: ARS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glenview, Illinois • Cincinnati, Ohio

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 13
States / cities: Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more

Conditions: Toxic Epidermal Necrolysis
Interventions: Clobetasol 0.05% ointment, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 7 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atopic Dermatitis, Secondary Infection
Interventions: Retapamulin 1%; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 2 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pruritus, Atopic Dermatitis
Interventions: Asimadoline, Placebo; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: silk fibroin-based incision dressing, cyanoacrylate-based closure system; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 14 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Stevens-Johnson Syndrome, Corneal Blindness
Interventions: Infliximab; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: ruxolitinib, ruxolitinib and an Eczema Action Plan; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions: Naltrexone, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atopic Dermatitis, Eczema
Interventions: Nanocrystalline silver cream (NPI); Drug
Lead sponsor: Nucryst Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 19
States / cities: Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more

Conditions: Atopic Dermatitis
Interventions: PF-04965842, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Encinitas, California • Pasadena, California + 32 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more

Conditions: Atopic Dermatitis
Interventions: KLH carrier-protein; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Stress-induced Scratching in Healthy and AD

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Study of Ravulizumab in Pediatric Participants With Primary IgAN

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Opzelura Experience Study

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route